Drug-price Transparency for Consumers Act of 2023
S 1250, the Drug-price Transparency for Consumers Act of 2023, requires pharmaceutical companies to disclose the wholesale acquisition cost (WAC) for a 30-day supply of prescription drugs in direct-to-consumer advertisements. This applies to drugs covered by Medicare or Medicaid, excluding those with a WAC under $35 per 30-day supply. The bill mandates clear display of the list price in ads, with manufacturers facing $100,000 penalties for noncompliance. It aims to give consumers upfront price information before they discuss prescriptions with doctors, helping them compare costs and make informed choices.
Bill status
in committee
1 of 4 stages cleared
Introduction
Apr 2023
Committee Review
Floor Vote
President
Introduced Apr 20, 2023
Last action Apr 20, 2023
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Apr 20, 2023
Committee
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298)
upper
Apr 20, 2023
Introduced
Introduced in Senate
upper
1 primary · 8 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about S 1250
Scope: US
Hi! I can help you understand S 1250. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline